Video

Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency

Author(s):

Saro Arakelians, PharmD

Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

Related Videos
Related Content
Research Shows Efgartigimod Costs Are Far Higher Than Therapeutic Plasma Exchange for Myasthenia Gravis
December 18th 2024

Research Shows Efgartigimod Costs Are Far Higher Than Therapeutic Plasma Exchange for Myasthenia Gravis

Aislinn Antrim, Assistant Managing Editor
man in hospital having an intravenous drip immunoglobulin infusion
December 16th 2024

IVIG Identified as a Treatment Marker of High Medical Costs, Resource Utilization in Patients With Myasthenia Gravis

Luke Halpern, Assistant Editor
Myelodysplastic Syndromes and Their Treatment Options: A Guide for Pharmacists
December 5th 2024

Myelodysplastic Syndromes and Their Treatment Options: A Guide for Pharmacists

Saro Arakelians, PharmD
Closeup irritated infected red bloodshot eyes, conjunctivitis
December 3rd 2024

High-Dose IVIG, Rituximab Effective in Patients With Pemphigoid-Associated Conjunctivitis

Luke Halpern, Assistant Editor
Technician holding blood tube test in the research laboratory / doctor hand taking a blood sample tube from a rack with machines of analysis in the lab background
November 28th 2024

Recent Intravenous Immunoglobulin Administration Can Lead to Serum Protein Electrophoresis Misdiagnosis

Luke Halpern, Assistant Editor
Multicolored antibodies or immunoglobulin protein structures - 3d illustration
November 23rd 2024

IVIG Demonstrates Effectiveness in Several Neuroimmune Conditions, Indicating Potential for Long COVID Treatment

Luke Halpern, Assistant Editor